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Abstract  
The Objectives of the study were to investigate whether 400 µg 
inhaled salbutamol influences 3 km running time-trial perfor-
mance and lung function in eucapnic voluntary hyperpnoea 
positive (EVH+ve) and negative (EVH-ve) individuals. Fourteen 
male participants (22.4 ± 1.6yrs; 76.4 ± 8.7kg; 1.80 ± 0.07 m); 
(7 EVH+ve; 7 EVH-ve) were recruited following written in-
formed consent. All participants undertook an EVH challenge to 
identify either EVH+ve ( ↓ FEV1>10%) or EVH-ve ( ↓
FEV1<10%). Participants performed three separate 3 km run-
ning time-trials in a low-humidity (20-25%) environment on a 
non-motorized treadmill, 15 minutes following inhalation of 
salbutamol (400 µg), placebo (non-active inhalant) or control 
(no inhalant), in a randomized, single-blind, repeated measures 
design. Forced vital capacity maneuvers were performed at 
baseline, 10 minutes post inhalation and post time-trial. Time to 
complete 3 km and lung function data were analyzed using 
mixed model repeated measures ANOVA. Significance was 
assumed at p < 0.05.  All EVH+ve participants had FEV1 falls 
from baseline between 10-25% post-challenge. There was no 
difference in performance time between trial conditions in 
EVH+ve (1012.7 ± 129.6s; 1002.4 ± 123.1s; 1015.9 ± 113.0s) (p 
= 0.774) and EVH-ve (962.1 ± 99.2s; 962.0 ± 76.2s; 950.8 ± 
84.9s) (p = 0.401) groups for salbutamol, placebo and control 
trials, respectively. Exercising heart rate was significantly higher 
(p = 0.05) in the salbutamol trial (183 ± 8 beatsˑmin-1) compared 
to control (180 ± 9 beatsˑmin-1) with a trend towards signifi-
cance (p=0.06) in the placebo trial (179 ± 9 beatsˑmin-1) for the 
pooled groups, no differences were seen between trials in groups 
individually. There was an increase in FEV1 in both EVH+ve 
(4.01 ± 0.8L; 4.26 ± 0.7L; 4.25 ± 0.5L) and EVH-ve (4.81 ± 
0.4L; 5.1 ± 0.4L; 5.1 ± 0.5L) groups which was significant post-
inhalation (p = 0.01; p = 0.02), but not post-time-trial (p = 0.27; 
p = 0.06), respectively, following salbutamol. EVH+ve partici-
pants did not demonstrate significant falls (>10% from baseline) 
in FEV1 following any time-trial. Administration of 400µg 
inhaled salbutamol does not improve 3 km time-trial perfor-
mance in either mild EVH+ve or EVH–ve individuals despite 
significantly increased HR and FEV1.  
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Introduction 
 
Athletes are more susceptible to exercise induced bron-
choconstriction (EIB) than the general population, with 
those affected being permitted to use up to 1600 µg (max 
of 800 µg in a 12 hour period) of inhaled salbutamol per 
day on an as needed basis for the relief of symptoms 
(Dickinson et al., 2006; 2011; Molphy et al., 2014; 
WADA, 2017). Inhaled salbutamol is the most common 
therapy used by athletes to provide acute prevention and 
reversibility for EIB (Fitch, 2006).   
The eucapnic voluntary hyperpnoea (EVH) chal-
lenge is recognized as a sensitive and specific indirect 
airway challenge to assist in the diagnosis of EIB in ath-
letic populations (Parsons et al., 2013). When EVH chal-
lenges are used as part of a screening program for EIB in 
athletes, some may present with an EVH positive chal-
lenge (EVH+ve) without having any previous history of 
EIB (Dickinson et al., 2006; Molphy et al., 2014). Our 
groups previous work has demonstrated that some athletes 
with a positive EVH challenge do not present with EIB 
following a field based exercise challenge (Dickinson et 
al., 2006). Recently Price et al., (2015) demonstrated that 
mild EVH challenge responses are not repeatable, demon-
strating the transient nature of mild EIB. Moreover, the 
environment in which sporting performance takes place 
can be a contributing factor for EIB, perhaps individuals 
with mild EVH+ve challenges would exhibit with EIB in 
a more bronchoprovocative environment, such as that of 
low humidity (Sue-Chu et al., 2012).  
Limited data exist to suggest whether exercise per-
formance is affected in athletes with no history of EIB, 
who present with a mild EVH+ve challenge (10% - 25% 
fall in FEV1; Price et al., 2014). Performance in time trials 
to exhaustion can improve considerably (50%) when 
asthmatic patients receive conventional inhaled cortico-
steroid therapy, largely due to an improvement in lung 
function and protection against bronchoconstriction 
(Haverkamp et al., 2007). It is therefore reasonable to 
assume that athletes with a mild EVH+ve challenge will 
experience improved endurance performance if they in-
hale salbutamol prior to exercise. However, Koch et al., 
(2015a; 2015b) reported inhalation of 400 µg salbutamol 
prior to 10 km cycling did not influence performance in 
EVH+ve cyclists. The 10 km cycling trial was completed 
in laboratory conditions, which has been shown to be an 
environment that is not particularly provocative for EIB 
(Dickinson et al., 2006) and perhaps in a more broncho-
provocative environment the studies by Koch et al., 
(2015a; 2015b) would have seen a performance decre-
ment in EVH+ve cyclists. Accordingly, the purpose of 
this study was to investigate the effect of 400 µg of in-
haled salbutamol on 3 km running time-trial performance 
in an EIB provocative environment (humidity 20-25% - 
the minimum humidity attainable in the environmental 
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chamber) in EVH+ve and EVH negative (EVH-ve) indi-
viduals, in line with the notion outlined by Sue-Chu et al., 
(2012) that dry air is more provocative for EIB.  
 
Methods 
 
Participants 
Following ethical approval from Liverpool John Moores 
University research ethics committee (Ethics No. 
P13SPS041), 14 male participants (age: 22.4 ± 1.6 years; 
weight: 76.4 ± 8.7 kg; height: 1.80 ± 0.07 m) volunteered 
to participate in the study providing their written informed 
consent. All participants were in good health, non-
smokers and took part in recreational sport and exercise 
activities for at least 3 hours per week. No participant had 
previously been diagnosed with asthma and/or EIB, all 
participants were free from chest infection for at least two 
weeks prior to testing. Participants were informed about 
the nature and the risks of the experimental procedures 
before their informed consent was obtained.  
Participants completed an EVH challenge to iden-
tify them as either EVH+ve or EVH–ve. Following two 
familiarization sessions participants completed 3 km 
running time trials on three occasions over three consecu-
tive weeks, to allow sufficient wash-out and recovery. 
Prior to each 3 km time trial participants either inhaled 
400 µg salbutamol, a placebo (inactive inhalant) or noth-
ing (control); the 3km time-trials were randomized using 
a Latin square design.    
 
Eucapnic Voluntary Hyperpnoea (EVH) Challenge 
All participants undertook maximal flow-volume maneu-
vers using a spirometer (Microlab ML3500, Cardinal 
Health, Basingstoke, UK). Flow-volume measures rec-
orded from each maximal flow-volume loop were; Forced 
Expiratory Volume in one second (FEV1), Forced Vital 
Capacity (FVC), FEV1:FVC ratio (FEV1/FVC%), Peak 
Expiratory Flow (PEF) and forced expiratory flow be-
tween 25% and 75% of FVC (FEF25–75). Three maximal 
flow-volume loops were measured to gain baseline 
measures and were accepted in accordance with European 
Respiratory Society and American Thoracic Society crite-
ria (Miller et al., 2005). 
If FEV1 was above 70% of the predicted value, 
participants completed an EVH challenge (Anderson et 
al., 2001). The EVH challenge required participants to 
maintain  target  minute  ventilation  (?̇?E)  of  85% of their  
predicted maximal voluntary ventilation rate (MVV) for 6 
minutes, calculated by multiplying their resting FEV1 by 
30. Participants inhaled air from a compressed gas cylin-
der (19 oC and 2% humidity) containing 21% Oxygen, 5% 
Carbon Dioxide and 74% Nitrogen, via a two way valve. 
Expired air passed through a dry gas meter to enable ?̇?E to 
be calculated. Following the completion of the EVH chal-
lenge maximal flow volume loops were measured in du-
plicate at 3, 5, 7, 10 and 15 minutes with the best FEV1 
for each time point being recorded. If participants FEV1 
fell >10% from baseline on two consecutive time points 
following the EVH challenge they were deemed EVH+ve. 
Once consecutive falls of 10% or more in FEV1 from the 
resting value were observed, participants inhaled 200 µg 
salbutamol, with spirometry measured 10 minutes post 
inhalation to confirm bronchoconstriction was reversible. 
Participants who did not experience a >10% fall in FEV1 
were placed in the EVH–ve group. 
 
3 km Running Time-Trial 
Following two familiarization sessions, each participant 
completed a 3 km time-trial, on a Woodway Curve non-
motorized treadmill (Woodway, Wisconsin), on three 
occasions in a randomized, single blind (salbutamol and 
placebo trials only), repeated measures design with a 
minimum of 7 days between trials (see Figure 1), a-priori 
power calculations for the 3 km running time-trial pre-
dicted that for an expected completion time of 1000 sec-
onds with a standard deviation of (2%) 20 seconds, a 
sample of size of 6 would significantly (p<0.05) predict a 
(2.5%) 25 second change in performance with 80% pow-
er. The 3 km time-trials were performed in an environ-
mental chamber (Sporting Edge, UK) at 18 °C, 20.9% O2, 
20%-25% humidity.  
Prior to each 3 km time-trial participants complet-
ed resting maximal flow-volume loops, performed in 
triplicate. Participants then inhaled (via pocket chamber) 
either four x 100 µg Salbutamol (400 μg), four inhalations 
of non-active inhalant (placebo), or control (nothing in-
haled). Ten minutes post-inhalation spirometry was re-
peated, before the completion of a standardized warm-up 
(5 minutes on a motorized treadmill at 10 kph); partici-
pants then began the performance time-trial on the curve 
non-motorized treadmill. Every 0.5 km of the 3 km time 
trial, heart rate (HR), oxygen consumption (?̇?O2), carbon 
dioxide production ( ?̇?CO2), respiratory exchange ratio 
(RER) and minute ventilation (?̇?E) were recorded using
 
 
 
 
 
 
 
                Figure 1. Schematic of the protocol used for each laboratory visit. 
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the Oxycon online gas analysis system (Oxycon, Care-
fusion, Kent, UK), as well as rating of perceived exertion 
(RPE) using the Borg Scale (Borg, 1982). The Oxycon 
sensor was connected to a rubber mouthpiece and partici-
pants exercised whilst wearing a nose clip, this was to 
avoid a humid microclimate that may have occurred with-
in a facemask. During each time trial the only feedback 
available to the participant was the distance covered. 
Blood lactate was analyzed via finger-tip capillary blood 
sample taken immediately post time-trial (Lactate Pro, 
Arkray Inc. Finland), followed by the measurement of 
maximal flow volume loops in triplicate at 5 minutes post 
time-trial, a-priori power calculations for the lung func-
tion tests predicted that for an expected FEV1 of 4.0 L 
with a standard deviation of 0.3 L, a sample of size of 5 
would significantly (p < 0.05) predict a (10%) 0.4 L 
change in lung function with 80% power. 
 
Statistical analysis 
Statistical analysis incorporated a two-way repeated 
measures analysis of variance (ANOVA) to compare 
completion times, HR, ?̇?E and RPE between groups and 
trial conditions during time-trial performance and blood 
lactate levels post-exercise, a bonferroni correction was 
applied to correct for multiple comparisons. Spirometry 
measurements were analyzed using a mixed model re-
peated measures ANOVA to compare between groups, 
between conditions and between time-points. Two-way 
repeated measures ANOVA was used to compare FEV1 
between groups post salbutamol administration. Signifi-
cance was set at p < 0.05 for all analyses. All data were 
reported as mean (±SD) unless otherwise stated. Statisti-
cal analysis was performed using the statistical package 
for the social sciences (SPSS v21, IBM, New York). 
 
Results 
 
Fourteen participants (7 EVH+ve; 7 EVH-ve) successful-
ly completed all trials, participant demographics and lung 
function are shown in Table 1. Predictions for maximum 
voluntary ventilation (MVV) were 124.1 L and 148.2 L 
(FEV1 x 30),  with  ?̇?E attained  during ?̇?O2peak tests meas- 
uring 121.1 L and 150.4 L, for EVH+ve and EVH-ve 
groups respectively, the ?̇?E attained during performance 
time-trials are displayed in Figure 2. 
 
Lung function values 
Post-inhalation FEV1 was greater in the salbutamol trial 
(4.26 ± 0.69 L; 5.05 ± 0.45 L) when compared with both 
the placebo trial (4.10 ± 0.7 L p = 0.04; 4.83 ± 0.53 L p = 
0.03) and control trial (4.03 ± 0.69 L p = 0.013; 4.84 ± 
0.44 L p = 0.003) for the EVH+ve group and the EVH-ve 
group, respectively. There was an increase in FEV1 in 
both EVH+ve (4.01 ± 0.8 L; 4.26 ± 0.7 L p = 0.01; 4.25 ± 
0.5 L p = 0.27) and EVH-ve (4.81 ± 0.4 L; 5.1 ± 0.4 L p = 
0.02; 5.1 ± 0.5 L p = 0.06) groups for baseline, post-
inhalation and post-time-trial, respectively following 
inhaled salbutamol, which was significant post-inhalation, 
but this significance was not sustained post time-trial. 
There was a strong trend towards significant differences 
in baseline FEV1 between EVH+ve and EVH–ve partici-
pants for the salbutamol trial (4.01 ± 0.86; 4.81 ± 0.45 p = 
0.05) and the placebo trial (4.06 ± 0.80; 4.82 ± 0.55 p = 
0.06) with a significant difference at baseline in the con-
trol trial (4.0 ± 0.73; 4.84 ± 0.46 p = 0.03).  There was no 
fall in FEV1 from post-inhalation to post time-trial in any 
of 3 km time trials (Figure 3). 
 
Performance variables 
There were no differences in 3 km completion time be-
tween EVH+ve and EVH-ve participants across any of 
the trials (Figure 4). There were no significant differences 
between post-exercise lactate values, VE, or VO2 during 
performance for any trial condition (Figure 2).  
When the groups were pooled there was a strong 
trend towards significant difference in mean HR between 
the salbutamol trial (183 ± 8 beatsˑmin-1) and both the 
placebo trial (180 ± 9 beatsˑmin-1; p = 0.06) and the con-
trol trial (180 ± 9 beatsˑmin-1; p = 0.05). However this 
difference was not apparent for the EVH+ve (183 ± 8; 
182 ± 8; 180 ± 10; beatsˑmin-1) and the EVH-ve groups 
(184 ± 8; 176 ± 9; 180 ± 8 beatsˑmin-1) for the salbutamol 
trial, the placebo trial and the control trial, respectively. 
There were no differences in ratings of perceived exertion 
(RPE) between groups or trial conditions (Figure 4).  
 
Table 1. Mean (±SD) Participant Demographics and Lung Function Values Pre- and Post-EVH Challenge for: EVH Positive 
Individuals (EVH+ve) and EVH Negative Individuals (EVH-ve)., alongside individual participant responses to EVH challenge. 
    Baseline Lung Function Post EVH† Lung Function   
 Group Height (m) 
Weight 
(kg) 
Age  
(yrs) 
FEV1*  
(L) 
% Predicted 
FEV1* 
FEV1*  
(L) 
% Predicted 
FEV1* 
% Change 
in FEV1* 
?̇?O2peak ǂ 
(mL·kg-1) 
 EVH+ve (n=7) 1.75 (.06) 71.7 (6.6) 22.7 (1.9) 4.13 (.83) 92.9 (13.1) 3.55 (.77) 81.92 (12.9) -14.4 (4.0) 43.8 (5.7) 
 EVH-ve (n=7) 1.84 (.04) 81.1 (8.1) 22.1 (1.1) 4.94 (.45) 102.6 (6.3) 4.64 (.41) 98.8 (6.6) -6 (2.4) 50.0 (5.6) 
EVH+ve EVH-ve 
(n) FEV1 (L) Post-EVH FEV1 % Change in FEV1 (n) FEV1 (L) Post-EVH FEV1 % Change in FEV1 
1 3.18 2.77 -12.9 % 1 4.24 4 -5.7 % 
2 3.98 3.55 -10.8 % 2 5.51 5.04 -8.5 % 
3 4.06 3.45 -15.02 % 3 5.12 4.8 -6.3 % 
4 3.8 2.9 -23.7 % 4 4.94 4.91 -0.6 % 
5 5.95 5.23 -12.1 % 5 4.31 4.01 -7.0 % 
6 3.51 3.04 -13.4 % 6 5.12 4.78 -6.6 % 
7 4.48 3.9 -12.9 % 7 5.34 4.94 -7.5 % 
* FEV1 - Forced Expiratory Volume in 1 Second; † EVH - Eucapnic Voluntary Hyperpnoea; ǂ ?̇?O2peak – Peak volume of oxygen consumed per kilo-
gram body mass per minute 
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Figure 2. Performance Variables for a) Completion Time; b) Post Time-Trial Lactate Values; c) Peak Minute Ventilation; d) 
Mean VO2 Values to compare changes within groups. 
 
 
 
 
 
Figure 3. Change in lung function from baseline to post inhalation and post time-trial between 
conditions and within groups. 
 
Discussion 
 
Therapeutic doses (i.e. 400 µg) of inhaled salbutamol do 
not improve 3 km time-trial performance in either 
EVH+ve or EVH-ve participants despite significantly 
increasing FEV1 and a strong trend towards increased 
exercising HR. The 3 km running time-trial performed in 
an EIB provocative environment failed to induce a fall in 
FEV1 in the EVH+ve group in either the control or place-
bo conditions. Our findings are similar to Koch et al., 
(2015a; 2015b) who conducted investigations into the 
effect of inhaled salbutamol on 10 km cycling time trial 
performance in a laboratory environment. Koch et al., 
(2015a; 2015b) reported increases in FEV1 in EVH+ve 
and EVH-ve cyclists post-bronchodilator but this did not 
translate to improved 10 km cycling performance in either 
males or females.  
We did not observe bronchoconstriction in our 
study following placebo and control 3 km time-trials, this 
may have been due to the fact that our EVH+ve partici-
pants were only mild responders and were not susceptible 
to bronchoconstriction induced by exercise. In fact, 5 out 
of 7 of  the  EVH+ve  group  had  a  post  EVH  challenge 
FEV1  fall  from  baseline  only  between  10%  and  15%  
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Figure 4. Comparisons between trial conditions for a) EVH+ve Group Heart Rate Values b) EVH+ve Group Ratings of Per-
ceived Exertion c) EVH-ve Group Heart Rate Values d) EVH-ve Group Ratings of Perceived Exertion. 
 
 
 
 
 
Figure 5. Individual percentage changes in FEV1 from baseline following EVH challenge and low humidity 
running time-trial in the control condition. 
 
(Table 1). Price et al. (2015) have demonstrated the tran-
sient nature of EIB in athletes with FEV1 falls between 10 
and 20% following EVH challenges. Whereas, Williams 
et al. (2015) have demonstrated that repeatability in the 
EVH challenge response occurs when FEV1 falls greater 
than 20% from baseline. The individual lung function 
changes following EVH challenge and the individual lung 
function changes following the low humidity time-trial 
have been presented in Figure 5, showing a markedly 
reduced bronchial hypersensitivity following the time-
trial in the mild EVH+ve group. Furthermore, Price et al. 
(2016) have recently suggested that a cut-off criterion of 
15% fall in FEV1 post EVH is more appropriate to con-
firm EIB diagnosis.  Therefore if our study had recruited 
participants with EVH challenge falls >20% from base-
line we may have observed different responses in FEV1 
post placebo and control 3 km time trials. Interestingly, 
only one of the EVH+ve participants exhibited with a 
>12% increase in FEV1 following bronchodilator, further 
suggesting that although a sufficient fall was seen post-
EVH, not all criteria were met (Pellegrino et al., 2005). 
We have demonstrated that individuals with a mild 
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positive EVH challenge who exercise in an EIB provoca-
tive environment do not experience any decrements in 
airway function without salbutamol or any improvements 
in exercise performance when both EVH+ve and EVH-ve 
individuals exercise following inhaled 400µg salbutamol. 
However, we have not measured any markers of airway 
injury/inflammation to indicate the protective effect that 
inhaled salbutamol may have. We know that athletes who 
regularly exercise in provocative environments are more 
susceptible to airway remodeling (Karjalainen et al., 
2000). Simpson et al. (2016) have also recently reported 
that the acute use of terbutaline can reduce airway in-
flammation and epithelial cell damage. It would therefore 
be premature to conclude that individuals with no history 
of EIB who have a mild positive response to the EVH 
challenge would not benefit from treatment. Future stud-
ies should investigate both acute and long term use of 
appropriate inhaled therapy in EVH+ve athletes whilst 
measuring markers of inflammation to assess the protec-
tive effect of the medication. 
The administration of a single acute dose of in-
haled short-acting β2-agonist (SABA) does not appear to 
affect exercise performance in either healthy individuals 
or individuals with a mild positive response to Mannitol 
challenge. Recently, however, a study performed by 
Kalsen et al. (2014) examined the acute administration of 
multiple inhaled β2-agonists simultaneously, at the 
WADA maximum permitted daily amounts (salbutamol – 
1600 µg; salmeterol – 200 µg; formoterol – 36 µg), in 
healthy and airway hyper-responsive (AHR) individuals. 
The findings from their study show a significant increase 
in FEV1 post-inhalation in both groups and also signifi-
cantly greater sprint performance and maximal voluntary 
contraction (MVC), however no consequent improvement 
in performance was seen in high-intensity exercise per-
formance.  
This is in contrast to the findings of Decorte et al. 
(2013) who found that there was an increased time to 
fatigue following salbutamol inhalation, with no im-
provement in MVC. These differences could be explained 
by the administration of multiple β2-agonists in the 
Kalsen et al. (2014) study which could have had a greater 
effect on the β2 adrenergic receptors due to greater sys-
temic availability of the drugs. With greater bioavailabil-
ity there is the possibility of more potent stimulation of 
skeletal muscle due to structural differences between the 
different β2-agonists which can improve the binding po-
tential and allow for a greater saturation, and therefore 
stimulation, of the adrenergic receptors, leading to greater 
force of contraction but also the possibility of a higher 
rate of fatigue of the muscle fibers (Hoffman, 2001).  
When considering study limitations, the present 
study may not have found any ergogenic effect of salbut-
amol due to the comparatively small doses used, however 
the doses administered were the recommended therapeutic 
limit. There remains the possibility that performance 
improvements may not have been seen because the pre-
sent investigation focused solely on endurance perfor-
mance. Recent work (Decorte et al., 2013; Hostrup et al., 
2014; Kalsen et al., 2014) has indicated that inhaled β2-
agonists may enhance strength and power performance 
but not endurance performance. The present study may 
also have not found a late response in lung function as the 
post-exercise spirometry was performed at a single time-
point 5 minutes post, BTS/ATS criteria (Parsons et al., 
2013) state that spirometry should be performed at regular 
intervals for a minimum of 15 minutes post-challenge. 
The present study design stipulated that if a fall of 10% or 
more was seen at the 5 minute stage post-challenge then 
follow-up spirometry would have been repeated at 10 
minutes to confirm bronchoconstriction, yet this did not 
occur in any individual. Another limitation was the need 
for a 5 minute warm-up prior to the 3 km running time-
trial, this could have induced a refractory period during 
the time-trial (Parsons et al., 2013) and bronchocon-
striction may not have been evident for this reason. How-
ever, upon ethical approval and risk assessment, a mini-
mum 5 minute warm-up was deemed necessary in order 
for individuals to undergo maximal running time-trial 
performance. 
 
Conclusions 
 
The findings of the present study highlight that there is a 
significant increase in FEV1 and heart rate with inhaled 
Salbutamol in both EVH–ve and EVH+ve individuals. 
However, these increases do not translate to improved 
performance during 3 km running time-trial. The low 
humidity environment (20-25%) did not induce a fall in 
FEV1 in mild EVH+ve individuals. Of note, EVH+ve 
athletes did not report any symptoms of EIB during any of 
the trials, highlighting that asymptomatic individuals with 
a mild positive EVH challenge (>10% <25% ↓FEV1) may 
not necessarily exhibit EIB. Although a one-off bout of 
exercise at low humidity may not result in significant 
bronchoconstriction, future research should examine the 
long-term impact of exercising in such conditions both 
with and without appropriate inhaler therapy in EVH+ve 
athletes with no previous history of asthma or EIB. 
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Key points 
 
•  Athletes with EIB require short-acting β2-agonists 
for the relief and/or prevention of symptoms during 
sporting performance which has the potential to be 
ergogenic.  
• The present study demonstrates that there is no ergo-
genic effect from their therapeutic use in healthy ac-
tive individuals during 3 km running time-trial per-
formance. 
• Athletes with mild EIB may exhibit airway hyper-
responsiveness in bronchoprovocative environments. 
• The present study demonstrates that individuals with 
a mild positive response to EVH challenge do not 
exhibit with EIB during intense exercise in a low 
humidity (20-25%) environment.  
 
 
AUTHOR BIOGRAPHY 
 
John MOLPHY  
Employment 
Post-doctoral researcher at the University 
of Kent  
Degree 
PhD 
Research interests 
Exercise-induced bronchoconstriction in 
elite athletes and the efficacy of current 
inhaled therapies during performance. 
E-mail: j.r.molphy@kent.ac.uk 
 
John DICKINSON  
Employment 
Reader in sport and exercise physiology 
at the University of Kent  
Degree 
PhD 
Research interests 
Breathing issues in elite athletes and 
novel techniques for their identification, 
treatment and prevention. 
E-mail: j.w.dickinson@kent.ac.uk 
 
Neil CHESTER  
Employment 
Senior lecturer in sport and exercise 
science at Liverpool John Moores Uni-
versity  
Degree 
PhD 
Research interests 
Ergogenic aids in elite sport 
E-mail: n.chester@ljmu.ac.uk 
Low humidity asthmatic exercise performance 
 
 
 
588 
 
Mike LOOSEMORE  
Employment 
Sports physician for the English Institute 
of Sport 
Degree 
MBBS PhD 
Research interests 
Ergogenic aids and also the pathophysi-
ology of boxing injuries. 
E-mail: mike.loosemore@eis2win.co.uk 
 
Gregory WHYTE  
Employment 
Professor of applied sport and exercise 
science at Liverpool John Moores Uni-
versity  
Degree 
PhD 
Research interests 
Cardiorespiratory aspects of sports per-
formance. 
E-mail: g.whyte@ljmu.ac.uk 
 
 Dr John Molphy 
University of Kent, Medway Campus, Chatham Maritime, Kent 
ME4 4AG, UK 
 
